Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens
Aims This study implements a physiologically‐based pharmacokinetic (PBPK) modelling approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens. Methods A PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism...
Saved in:
| Published in: | British journal of clinical pharmacology Vol. 88; no. 4; pp. 1735 - 1750 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01.02.2022
|
| Subjects: | |
| ISSN: | 0306-5251, 1365-2125, 1365-2125 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Aims
This study implements a physiologically‐based pharmacokinetic (PBPK) modelling approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens.
Methods
A PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism and clinical pharmacokinetic data. The model accounts for ethnic differences in body size and abundance of drug‐metabolising enzymes and proteins involved in imatinib disposition. Utility of this model for prediction of imatinib pharmacokinetics was evaluated across different dosing regimens and ethnic groups. The impact of ethnicity on imatinib dosing was then assessed based on the established range of trough concentrations (Css,min).
Results
The PBPK model of imatinib demonstrated excellent predictive performance in describing pharmacokinetics and the attained Css,min in patients from different ethnic groups, shown by prediction differences that were within 1.25‐fold of the clinically‐reported values in published studies. PBPK simulation suggested a similar dose of imatinib (400–600 mg/d) to achieve the desirable range of Css,min (1000–3200 ng/mL) in populations of European, Japanese and Chinese ancestry. The simulation indicated that patients of African ancestry may benefit from a higher initial dose (600–800 mg/d) to achieve imatinib target concentrations, due to a higher apparent clearance (CL/F) of imatinib compared to other ethnic groups; however, the clinical data to support this are currently limited.
Conclusion
PBPK simulations highlighted a potential ethnic difference in the recommended initial dose of imatinib between populations of European and African ancestry, but not populations of Chinese and Japanese ancestry. |
|---|---|
| AbstractList | Aims
This study implements a physiologically‐based pharmacokinetic (PBPK) modelling approach to investigate inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens.
Methods
A PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism and clinical pharmacokinetic data. The model accounts for ethnic differences in body size and abundance of drug‐metabolising enzymes and proteins involved in imatinib disposition. Utility of this model for prediction of imatinib pharmacokinetics was evaluated across different dosing regimens and ethnic groups. The impact of ethnicity on imatinib dosing was then assessed based on the established range of trough concentrations (Css,min).
Results
The PBPK model of imatinib demonstrated excellent predictive performance in describing pharmacokinetics and the attained Css,min in patients from different ethnic groups, shown by prediction differences that were within 1.25‐fold of the clinically‐reported values in published studies. PBPK simulation suggested a similar dose of imatinib (400–600 mg/d) to achieve the desirable range of Css,min (1000–3200 ng/mL) in populations of European, Japanese and Chinese ancestry. The simulation indicated that patients of African ancestry may benefit from a higher initial dose (600–800 mg/d) to achieve imatinib target concentrations, due to a higher apparent clearance (CL/F) of imatinib compared to other ethnic groups; however, the clinical data to support this are currently limited.
Conclusion
PBPK simulations highlighted a potential ethnic difference in the recommended initial dose of imatinib between populations of European and African ancestry, but not populations of Chinese and Japanese ancestry. This study implements a physiologically-based pharmacokinetic (PBPK) modelling approach to investigate inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. A PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism and clinical pharmacokinetic data. The model accounts for ethnic differences in body size and abundance of drug-metabolising enzymes and proteins involved in imatinib disposition. Utility of this model for prediction of imatinib pharmacokinetics was evaluated across different dosing regimens and ethnic groups. The impact of ethnicity on imatinib dosing was then assessed based on the established range of trough concentrations (C ). The PBPK model of imatinib demonstrated excellent predictive performance in describing pharmacokinetics and the attained C in patients from different ethnic groups, shown by prediction differences that were within 1.25-fold of the clinically-reported values in published studies. PBPK simulation suggested a similar dose of imatinib (400-600 mg/d) to achieve the desirable range of C (1000-3200 ng/mL) in populations of European, Japanese and Chinese ancestry. The simulation indicated that patients of African ancestry may benefit from a higher initial dose (600-800 mg/d) to achieve imatinib target concentrations, due to a higher apparent clearance (CL/F) of imatinib compared to other ethnic groups; however, the clinical data to support this are currently limited. PBPK simulations highlighted a potential ethnic difference in the recommended initial dose of imatinib between populations of European and African ancestry, but not populations of Chinese and Japanese ancestry. This study implements a physiologically-based pharmacokinetic (PBPK) modelling approach to investigate inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.AIMSThis study implements a physiologically-based pharmacokinetic (PBPK) modelling approach to investigate inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.A PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism and clinical pharmacokinetic data. The model accounts for ethnic differences in body size and abundance of drug-metabolising enzymes and proteins involved in imatinib disposition. Utility of this model for prediction of imatinib pharmacokinetics was evaluated across different dosing regimens and ethnic groups. The impact of ethnicity on imatinib dosing was then assessed based on the established range of trough concentrations (Css,min ).METHODSA PBPK model of imatinib was built in the Simcyp Simulator (version 17) integrating in vitro drug metabolism and clinical pharmacokinetic data. The model accounts for ethnic differences in body size and abundance of drug-metabolising enzymes and proteins involved in imatinib disposition. Utility of this model for prediction of imatinib pharmacokinetics was evaluated across different dosing regimens and ethnic groups. The impact of ethnicity on imatinib dosing was then assessed based on the established range of trough concentrations (Css,min ).The PBPK model of imatinib demonstrated excellent predictive performance in describing pharmacokinetics and the attained Css,min in patients from different ethnic groups, shown by prediction differences that were within 1.25-fold of the clinically-reported values in published studies. PBPK simulation suggested a similar dose of imatinib (400-600 mg/d) to achieve the desirable range of Css,min (1000-3200 ng/mL) in populations of European, Japanese and Chinese ancestry. The simulation indicated that patients of African ancestry may benefit from a higher initial dose (600-800 mg/d) to achieve imatinib target concentrations, due to a higher apparent clearance (CL/F) of imatinib compared to other ethnic groups; however, the clinical data to support this are currently limited.RESULTSThe PBPK model of imatinib demonstrated excellent predictive performance in describing pharmacokinetics and the attained Css,min in patients from different ethnic groups, shown by prediction differences that were within 1.25-fold of the clinically-reported values in published studies. PBPK simulation suggested a similar dose of imatinib (400-600 mg/d) to achieve the desirable range of Css,min (1000-3200 ng/mL) in populations of European, Japanese and Chinese ancestry. The simulation indicated that patients of African ancestry may benefit from a higher initial dose (600-800 mg/d) to achieve imatinib target concentrations, due to a higher apparent clearance (CL/F) of imatinib compared to other ethnic groups; however, the clinical data to support this are currently limited.PBPK simulations highlighted a potential ethnic difference in the recommended initial dose of imatinib between populations of European and African ancestry, but not populations of Chinese and Japanese ancestry.CONCLUSIONPBPK simulations highlighted a potential ethnic difference in the recommended initial dose of imatinib between populations of European and African ancestry, but not populations of Chinese and Japanese ancestry. |
| Author | Boddy, Alan V. Gross, Annette S. McLachlan, Andrew J. Adiwidjaja, Jeffry |
| Author_xml | – sequence: 1 givenname: Jeffry orcidid: 0000-0002-6781-2113 surname: Adiwidjaja fullname: Adiwidjaja, Jeffry organization: Gadjah Mada University – sequence: 2 givenname: Annette S. orcidid: 0000-0001-9567-0127 surname: Gross fullname: Gross, Annette S. organization: Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D – sequence: 3 givenname: Alan V. orcidid: 0000-0002-8920-9286 surname: Boddy fullname: Boddy, Alan V. organization: University of South Australia – sequence: 4 givenname: Andrew J. orcidid: 0000-0003-4674-0242 surname: McLachlan fullname: McLachlan, Andrew J. email: andrew.mclachlan@sydney.edu.au organization: The University of Sydney |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34535920$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kb1uFDEUhS0URDaBghdALqGYxP-ZKWHFnxSJFFBbHvt61-CxB3tW0XaUlDwjT4LDbpoIbnOL-50j3XPO0EnKCRB6TskFbXM52vmCStKLR2hFuZIdo0yeoBXhRHWSSXqKzmr9SgjlVMkn6JQLyeXAyAr9vNnua8gxb4I1Me5___g1mgoOz1tTJmPzt5BgCRZP2UHEcwEX7BJyqjh7HNICpUlg2abGuOA9FEgWajvhMJklpDA-9KrYJIddriFtcIFNmCDVp-ixN7HCs-M-R1_evf28_tBdf3r_cf36urNcEdFxOgg_AnNylN73YhBMGqOkpcCtvHKe9VQNg5ecSzCDtT0oRahvUVgpHPBz9PLgO5f8fQd10VOoFmI0CfKuaiavhCCKib6hL47obpzA6bm0j8pe36fXgMsDYEuutYDXNizmLp2lmBA1JfquH9360X_7aYpXDxT3pv9ij-63IcL-_6B-s745KP4AgxGkCg |
| CitedBy_id | crossref_primary_10_1124_dmd_123_001430 crossref_primary_10_1007_s00280_023_04566_z crossref_primary_10_5937_hpimj2502692T crossref_primary_10_1002_jcph_2065 crossref_primary_10_1007_s11030_023_10604_y crossref_primary_10_1002_psp4_13305 crossref_primary_10_1002_psp4_70018 crossref_primary_10_1002_psp4_13127 crossref_primary_10_1038_s41598_023_43258_9 crossref_primary_10_1124_pharmrev_124_001049 crossref_primary_10_1007_s00280_023_04598_5 crossref_primary_10_3389_fphar_2023_1234262 crossref_primary_10_1021_acsomega_4c09472 crossref_primary_10_1007_s13318_023_00868_y crossref_primary_10_1002_cpt_2591 crossref_primary_10_1002_prp2_1082 crossref_primary_10_1016_j_jchromb_2024_124001 |
| Cites_doi | 10.1111/j.1365-2125.2006.02719.x 10.1016/j.leukres.2010.09.014 10.1002/cpt.1076 10.1002/cpt.1240 10.1159/000484102 10.1111/bph.14753 10.1016/j.clinthera.2019.10.009 10.1200/JCO.2009.25.3724 10.1182/blood-2007-10-116475 10.1007/s40261-020-00921-7 10.1158/1078-0432.CCR-07-0346 10.1016/j.clinbiochem.2016.12.006 10.2217/pgs-2018-0139 10.1038/clpt.1990.111 10.1002/cpt.787 10.1182/blood-2006-07-036012 10.1124/jpet.116.233635 10.1002/psp4.12615 10.1002/jcph.953 10.1002/bdd.2257 10.1002/bdd.1987 10.1007/s00280-003-0756-z 10.1007/s40262-013-0089-y 10.1016/j.tips.2016.08.003 10.3390/ijms18030603 10.1111/bcp.13327 10.2217/pgs.09.82 10.1124/jpet.102.033837 10.1038/leu.2008.245 10.1097/FTD.0b013e318284ef11 10.1158/1078-0432.CCR-05-2596 10.1038/clpt.2012.68 10.1016/j.clpt.2006.05.003 10.1124/dmd.114.058099 10.1002/jps.24113 10.18433/jpps30559 10.1592/phco.24.16.1508.50958 10.1007/s12185-011-0838-3 10.1038/clpt.2010.186 10.1124/dmd.109.031542 10.1111/bcp.13990 10.1200/jco.2010.28.15_suppl.e13034 10.3389/fphar.2019.00854 10.1111/j.1476-5381.2010.00946.x 10.1038/sj.clpt.6100201 10.18433/J3159D 10.1007/s00277-013-1937-4 10.1111/jcpt.12424 10.1007/s12185-009-0263-z 10.1016/j.leukres.2008.07.015 10.2174/138920008784746382 10.1002/psp4.12034 10.1080/10826076.2015.1025143 10.1016/j.jshs.2016.01.019 10.1111/j.1365-2125.2004.02117.x 10.1080/00498250600683262 10.3322/caac.21551 10.1093/annonc/mdx219 10.1093/jnci/djr060 10.1016/j.ijid.2016.10.008 10.1038/clpt.2013.92 10.1124/dmd.105.004283 10.1007/s12185-009-0315-4 10.1007/s00228-015-1834-y 10.1007/s40262-016-0494-0 10.1159/000336244 10.1111/j.1365-2125.2011.04076.x 10.1124/dmd.112.048017 10.1007/s40262-016-0441-0 10.1016/j.ejps.2009.12.002 10.1038/aps.2010.79 10.1111/bcp.12702 10.2174/157488408785747656 10.1111/j.1365-2125.2012.04422.x 10.3389/fphar.2019.01672 10.1111/ped.12382 10.1016/j.ejps.2020.105355 10.1007/s00228-012-1467-3 10.1056/NEJMoa1609324 10.1007/s00228-020-02888-y 10.1200/JCO.2009.26.3087 10.1111/j.1349-7006.2010.01643.x 10.1111/bcp.13764 10.1007/s40262-019-00736-6 10.1038/aps.2015.122 10.1111/bph.14752 10.1007/s40262-015-0356-1 10.1111/j.1476-5381.2011.01732.x 10.1111/j.1365-2125.2008.03150.x 10.3324/haematol.2011.045666 10.1016/j.ejca.2015.12.029 10.1158/1078-0432.CCR-08-0950 10.1002/psp4.12088 10.1007/s10147-007-0746-y 10.1093/chromsci/bmt037 10.1007/s40262-016-0439-7 10.1111/j.1349-7006.2012.02253.x 10.1007/s00280-003-0722-9 10.1002/psp4.12392 10.21037/tcr.2017.09.08 |
| ContentType | Journal Article |
| Copyright | 2021 British Pharmacological Society 2021 British Pharmacological Society. |
| Copyright_xml | – notice: 2021 British Pharmacological Society – notice: 2021 British Pharmacological Society. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1111/bcp.15084 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 1750 |
| ExternalDocumentID | 34535920 10_1111_bcp_15084 BCP15084 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Indonesia Endowment Fund for Education (LPDP), Ministry of Finance of the Republic of Indonesia |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X NPM 7X8 |
| ID | FETCH-LOGICAL-c3604-3194fbe2d5b5ff849425aa65c1e3c57df281699f5335ea9cc8e6601f030c54de3 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000707392800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Fri Jul 11 09:36:34 EDT 2025 Thu Apr 03 07:09:17 EDT 2025 Tue Nov 18 22:01:49 EST 2025 Sat Nov 29 03:17:10 EST 2025 Wed Jan 22 16:25:03 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | imatinib physiologically-based pharmacokinetic simulation ethnic differences |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2021 British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3604-3194fbe2d5b5ff849425aa65c1e3c57df281699f5335ea9cc8e6601f030c54de3 |
| Notes | Funding information Indonesia Endowment Fund for Education (LPDP), Ministry of Finance of the Republic of Indonesia ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8920-9286 0000-0001-9567-0127 0000-0002-6781-2113 0000-0003-4674-0242 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15084 |
| PMID | 34535920 |
| PQID | 2574406248 |
| PQPubID | 23479 |
| PageCount | 16 |
| ParticipantIDs | proquest_miscellaneous_2574406248 pubmed_primary_34535920 crossref_citationtrail_10_1111_bcp_15084 crossref_primary_10_1111_bcp_15084 wiley_primary_10_1111_bcp_15084_BCP15084 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2022 |
| References | 2009; 89 2017; 83 2017; 6 2015; 36 2012; 165 2013; 69 2015; 38 2013; 1 2015; 71 2019; 10 2006; 36 2010; 101 2004; 24 2019; 58 2008; 9 2015; 80 2008; 3 2020; 10 2007; 109 2012; 127 2016; 37 2012; 97 2009; 10 2006; 62 1990; 48 2019; 20 2010; 28 2013; 94 2013; 52 2003; 9 2019; 69 2016; 41 2002; 302 2008; 65 2016; 358 2014; 52 2008; 111 2014; 93 2005; 33 2014; 56 2018; 36 2019; 8 2009; 23 2010; 31 2010; 38 2021; 42 2015; 4 2006; 12 2017; 28 2020; 40 2010; 39 2018; 104 2013; 41 2008; 14 2019; 105 2011; 33 2008; 13 2010; 161 2011; 35 2020; 76 2012; 103 2017; 376 2007; 10 2007; 13 2016; 57 2016; 55 2012; 73 2014; 42 2016; 5 2010; 88 2009; 33 2017; 50 2011; 103 2012; 92 2004; 53 2006; 80 2021; 10 2019; 85 2019; 41 2013; 35 2004; 58 2011; 93 2017; 57 2013; 75 2017; 56 2020; 150 2016 2007; 82 2015 2020; 23 2017; 18 2019; 139 2017; 102 2018; 97 2014; 103 2019; 176 e_1_2_11_70_1 e_1_2_11_93_1 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_78_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_74_1 e_1_2_11_97_1 e_1_2_11_13_1 e_1_2_11_29_1 e_1_2_11_4_1 e_1_2_11_106_1 e_1_2_11_48_1 e_1_2_11_102_1 Zhou L (e_1_2_11_27_1) 2019; 139 e_1_2_11_81_1 Jamei M (e_1_2_11_30_1) 2013; 1 e_1_2_11_20_1 e_1_2_11_66_1 e_1_2_11_47_1 e_1_2_11_24_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_85_1 e_1_2_11_17_1 e_1_2_11_59_1 e_1_2_11_50_1 e_1_2_11_92_1 e_1_2_11_58_1 e_1_2_11_35_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_54_1 e_1_2_11_96_1 e_1_2_11_103_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_61_1 e_1_2_11_80_1 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_88_1 e_1_2_11_107_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_84_1 e_1_2_11_16_1 e_1_2_11_39_1 Smith SA (e_1_2_11_77_1) 2018; 36 Yamakawa Y (e_1_2_11_89_1) 2011; 33 e_1_2_11_72_1 e_1_2_11_91_1 Gambacorti‐Passerini C (e_1_2_11_43_1) 2003; 9 e_1_2_11_57_1 e_1_2_11_99_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_76_1 e_1_2_11_95_1 e_1_2_11_11_1 e_1_2_11_6_1 e_1_2_11_104_1 e_1_2_11_2_1 e_1_2_11_100_1 Rowland‐Yeo K (e_1_2_11_31_1) 2010; 39 e_1_2_11_83_1 e_1_2_11_60_1 e_1_2_11_45_1 e_1_2_11_68_1 e_1_2_11_41_1 e_1_2_11_87_1 e_1_2_11_108_1 e_1_2_11_22_1 e_1_2_11_64_1 e_1_2_11_15_1 e_1_2_11_38_1 e_1_2_11_19_1 e_1_2_11_94_1 e_1_2_11_71_1 e_1_2_11_90_1 e_1_2_11_10_1 e_1_2_11_56_1 e_1_2_11_79_1 e_1_2_11_14_1 e_1_2_11_52_1 e_1_2_11_98_1 e_1_2_11_33_1 e_1_2_11_75_1 e_1_2_11_7_1 e_1_2_11_105_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 e_1_2_11_101_1 e_1_2_11_82_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_86_1 e_1_2_11_18_1 e_1_2_11_37_1 |
| References_xml | – volume: 69 start-page: 7 issue: 1 year: 2019 end-page: 34 article-title: Cancer statistics, 2019 publication-title: CA Cancer J Clin – volume: 10 start-page: 420 issue: 5 year: 2021 end-page: 427 article-title: Opening a debate on open‐source modeling tools: pouring fuel on fire versus extinguishing the flare of a healthy debate publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 55 start-page: 823 issue: 7 year: 2016 end-page: 832 article-title: Combining 'bottom‐up' and 'top‐down' methods to assess ethnic difference in clearance: bitopertin as an example publication-title: Clin Pharmacokinet – volume: 139 start-page: 1 issue: 105061 year: 2019 end-page: 10 article-title: Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically‐based pharmacokinetic modelling publication-title: Eur J Pharm Sci – volume: 10 start-page: 411 issue: 4 year: 2007 end-page: 419 article-title: Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects publication-title: J Pharm Pharm Sci – volume: 3 start-page: 198 issue: 3 year: 2008 end-page: 203 article-title: Influence of enzyme‐inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients publication-title: Curr Clin Pharmacol – volume: 28 start-page: iv41 year: 2017 end-page: iv51 article-title: Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up publication-title: Ann Oncol – volume: 42 start-page: 107 issue: 4 year: 2021 end-page: 117 article-title: Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms publication-title: Biopharm Drug Dispos – volume: 93 start-page: 618 issue: 5 year: 2011 end-page: 623 article-title: Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia publication-title: Int J Hematol – volume: 12 start-page: 6073 issue: 20 year: 2006 end-page: 6078 article-title: Pharmacokinetic‐pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors publication-title: Clin Cancer Res – volume: 1 start-page: 1 issue: 9 year: 2013 end-page: 14 article-title: The Simcyp population based simulator: architecture, implementation, and quality assurance publication-title: In Silico Pharmacol – volume: 165 start-page: 2787 issue: 8 year: 2012 end-page: 2798 article-title: Potent mechanism‐based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates publication-title: Br J Pharmacol – volume: 57 start-page: 1554 issue: 12 year: 2017 end-page: 1563 article-title: Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance publication-title: J Clin Pharmacol – volume: 28 start-page: 2381 issue: 14 year: 2010 end-page: 2388 article-title: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib publication-title: J Clin Oncol – volume: 102 start-page: 765 issue: 5 year: 2017 end-page: 776 article-title: Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology publication-title: Clin Pharmacol Ther – volume: 94 start-page: 383 issue: 3 year: 2013 end-page: 393 article-title: Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8‐mediated formation of its main metabolite publication-title: Clin Pharmacol Ther – volume: 75 start-page: 1007 issue: 4 year: 2013 end-page: 1018 article-title: Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours publication-title: Br J Clin Pharmacol – volume: 39 start-page: 298 issue: 5 year: 2010 end-page: 309 article-title: Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time‐dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—the effect of diltiazem on the time‐course of exposure to triazolam publication-title: Eur J Pharm Sci – volume: 65 start-page: 885 issue: 6 year: 2008 end-page: 892 article-title: Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia publication-title: Br J Clin Pharmacol – volume: 80 start-page: 534 issue: 3 year: 2015 end-page: 547 article-title: Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically‐based pharmacokinetic modelling: application to docetaxel publication-title: Br J Clin Pharmacol – volume: 33 start-page: 244 issue: 2 year: 2011 end-page: 250 article-title: Association of genetic polymorphisms in the influx transporter and the efflux transporter with imatinib pharmacokinetics in patients with chronic myeloid leukemia publication-title: Ther Drug Monit – volume: 37 start-page: 904 issue: 11 year: 2016 end-page: 932 article-title: Impact of membrane drug transporters on resistance to small‐molecule tyrosine kinase inhibitors publication-title: Trends Pharmacol Sci – volume: 105 start-page: 1018 issue: 4 year: 2019 end-page: 1030 article-title: Application of physiologically based pharmacokinetic modeling to predict pharmacokinetics in healthy Japanese subjects publication-title: Clin Pharmacol Ther – volume: 85 start-page: 1994 issue: 9 year: 2019 end-page: 2001 article-title: Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumors: a cost‐effectiveness study publication-title: Br J Clin Pharmacol – volume: 41 start-page: 50 issue: 1 year: 2013 end-page: 59 article-title: Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response publication-title: Drug Metab Dispos – volume: 13 start-page: 244 issue: 3 year: 2008 end-page: 251 article-title: Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) publication-title: Int J Clin Oncol – volume: 35 start-page: e11 issue: 1 year: 2011 end-page: e12 article-title: Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia? publication-title: Leuk Res – volume: 23 start-page: 602 issue: 3 year: 2009 end-page: 604 article-title: Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR‐ABL‐positive CML and other chronic myeloproliferative disorders in a representative area in Germany publication-title: Leukemia – volume: 176 start-page: S297 year: 2019 end-page: S396 article-title: The Concise Guide to PHARMACOLOGY 2019/20: Enzymes publication-title: Br J Pharmacol – volume: 83 start-page: 2195 issue: 10 year: 2017 end-page: 2204 article-title: Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib publication-title: Br J Clin Pharmacol – volume: 23 start-page: 1 issue: 1 year: 2020 end-page: 9 article-title: Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in Chinese patients with chronic myeloid leukemia publication-title: J Pharm Pharm Sci – volume: 10 start-page: 1672 year: 2020 article-title: Implementation of a physiologically based pharmacokinetic modelling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics publication-title: Front Pharmacol – volume: 176 start-page: S397 year: 2019 end-page: S493 article-title: The Concise Guide to PHARMACOLOGY 2019/20: Transporters publication-title: Br J Pharmacol – volume: 35 start-page: 150 issue: 2 year: 2013 end-page: 167 article-title: Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes publication-title: Ther Drug Monit – volume: 69 start-page: 1311 issue: 6 year: 2013 end-page: 1320 article-title: Application of in vitro‐in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure publication-title: Eur J Clin Pharmacol – volume: 20 start-page: 251 issue: 4 year: 2019 end-page: 260 article-title: Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia publication-title: Pharmacogenomics – volume: 89 start-page: 319 issue: 3 year: 2009 end-page: 325 article-title: Long‐term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group publication-title: Int J Hematol – volume: 52 start-page: 1085 issue: 12 year: 2013 end-page: 1100 article-title: Differences in cytochrome P450‐mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling publication-title: Clin Pharmacokinet – volume: 53 start-page: 102 issue: 2 year: 2004 end-page: 106 article-title: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects publication-title: Cancer Chemother Pharmacol – volume: 358 start-page: 83 issue: 1 year: 2016 end-page: 93 article-title: Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes publication-title: J Pharmacol Exp Ther – volume: 376 start-page: 917 issue: 10 year: 2017 end-page: 927 article-title: Long‐term outcomes of imatinib treatment for chronic myeloid leukemia publication-title: N Engl J Med – volume: 38 start-page: 889 issue: 6 year: 2010 end-page: 893 article-title: Human liver expression of CYP2C8: gender, age, and genotype effects publication-title: Drug Metab Dispos – volume: 41 start-page: 546 issue: 5 year: 2016 end-page: 551 article-title: Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia publication-title: J Clin Pharm Ther – year: 2016 – volume: 93 start-page: 71 issue: 1 year: 2014 end-page: 80 article-title: Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV publication-title: Ann Hematol – volume: 150 start-page: 105355 year: 2020 article-title: A physiologically based pharmacokinetic‐pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug–drug interactions of paclitaxel in cancer patients publication-title: Eur J Pharm Sci – volume: 56 start-page: e33 issue: 4 year: 2014 end-page: e36 article-title: Carbamazepine‐imatinib interaction in a child with chronic myeloid leukemia publication-title: Pediatr Int – volume: 36 start-page: 1 issue: 2 year: 2018 end-page: 19 article-title: Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha‐1‐acid glycoprotein publication-title: Pharm Res – volume: 24 start-page: 1508 issue: 11 year: 2004 end-page: 1514 article-title: The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate publication-title: Pharmacotherapy – volume: 62 start-page: 97 issue: 1 year: 2006 end-page: 112 article-title: Population pharmacokinetics of imatinib and the role of alpha‐acid glycoprotein publication-title: Br J Clin Pharmacol – volume: 36 start-page: 499 issue: 6 year: 2006 end-page: 513 article-title: Prediction of in vivo drug clearance from in vitro data. II: potential inter‐ethnic differences publication-title: Xenobiotica – volume: 33 start-page: 271 issue: 2 year: 2009 end-page: 275 article-title: Cytogenetic and molecular responses to standard‐dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels publication-title: Leuk Res – volume: 56 start-page: 208 issue: 35 year: 2017 end-page: 211 article-title: Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches publication-title: Int J Infect Dis – volume: 52 start-page: 344 issue: 4 year: 2014 end-page: 350 article-title: LC‐MS‐MS determination of imatinib and N‐desmethyl imatinib in human plasma publication-title: J Chromatogr Sci – volume: 56 start-page: 287 issue: 3 year: 2017 end-page: 292 article-title: Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients publication-title: Clin Pharmacokinet – volume: 58 start-page: 212 issue: 2 year: 2004 end-page: 216 article-title: In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia publication-title: Br J Clin Pharmacol – volume: 42 start-page: 1478 issue: 9 year: 2014 end-page: 1484 article-title: Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations publication-title: Drug Metab Dispos – volume: 40 start-page: 617 issue: 7 year: 2020 end-page: 628 article-title: Effect of cytochrome P450 and polymorphisms on imatinib pharmacokinetics after single‐dose administration to healthy subjects publication-title: Clin Drug Investig – volume: 8 start-page: 273 issue: 5 year: 2019 end-page: 284 article-title: A theoretical physiologically‐based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 89 start-page: 642 issue: 5 year: 2009 end-page: 648 article-title: Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia publication-title: Int J Hematol – volume: 73 start-page: 268 issue: 2 year: 2012 end-page: 284 article-title: Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes publication-title: Br J Clin Pharmacol – volume: 53 start-page: 433 issue: 5 year: 2004 end-page: 438 article-title: Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules publication-title: Cancer Chemother Pharmacol – volume: 9 start-page: 384 issue: 5 year: 2008 end-page: 394 article-title: Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions publication-title: Curr Drug Metab – volume: 6 start-page: S1541 year: 2017 end-page: S1557 article-title: Role of pharmacogenetics in personalised imatinib dosing publication-title: Transl Cancer Res – volume: 88 start-page: 809 issue: 6 year: 2010 end-page: 813 article-title: Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic‐phase chronic myeloid leukemia publication-title: Clin Pharmacol Ther – volume: 28 start-page: 424 issue: 3 year: 2010 end-page: 430 article-title: Phase III, randomized, open‐label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study publication-title: J Clin Oncol – volume: 97 start-page: 20 issue: 1 year: 2018 end-page: 25 article-title: Long‐term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors publication-title: Digestion – volume: 41 start-page: 2558 issue: 12 year: 2019 end-page: 2570 article-title: Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta‐analysis publication-title: Clin Ther – volume: 103 start-page: 1071 issue: 6 year: 2012 end-page: 1078 article-title: Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study publication-title: Cancer Sci – volume: 80 start-page: 192 issue: 2 year: 2006 end-page: 201 article-title: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib publication-title: Clin Pharmacol Ther – volume: 82 start-page: 33 issue: 1 year: 2007 end-page: 40 article-title: Imatinib disposition and (MDR1, P‐glycoprotein) genotype publication-title: Clin Pharmacol Ther – volume: 76 start-page: 1075 issue: 8 year: 2020 end-page: 1082 article-title: Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib‐d8 microdose publication-title: Eur J Clin Pharmacol – volume: 56 start-page: 305 issue: 3 year: 2017 end-page: 310 article-title: Prospective analysis in GIST patients on the role of alpha‐1 acid glycoprotein in imatinib exposure publication-title: Clin Pharmacokinet – volume: 109 start-page: 3496 issue: 8 year: 2007 end-page: 3499 article-title: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard‐dose imatinib in chronic myeloid leukemia publication-title: Blood – volume: 9 start-page: 625 issue: 2 year: 2003 end-page: 632 article-title: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients publication-title: Clin Cancer Res – volume: 38 start-page: 1194 issue: 12 year: 2015 end-page: 1198 article-title: Simple HPLC‐UV method for pharmacokinetic studies of imatinib in the presence of common antimalaria agents publication-title: J Liq Chromatogr Relat Technol – volume: 48 start-page: 10 issue: 1 year: 1990 end-page: 17 article-title: Differences in plasma binding of drugs between Caucasians and Chinese subjects publication-title: Clin Pharmacol Ther – volume: 31 start-page: 999 issue: 8 year: 2010 end-page: 1004 article-title: Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients publication-title: Acta Pharmacol Sin – volume: 97 start-page: 731 issue: 5 year: 2012 end-page: 738 article-title: Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial publication-title: Haematologica – volume: 10 start-page: 1489 issue: 9 year: 2009 end-page: 1510 article-title: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies publication-title: Pharmacogenomics – volume: 104 start-page: 1219 issue: 6 year: 2018 end-page: 1228 article-title: Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure publication-title: Clin Pharmacol Ther – volume: 161 start-page: 1059 issue: 5 year: 2010 end-page: 1069 article-title: Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes publication-title: Br J Pharmacol – volume: 103 start-page: 3810 issue: 12 year: 2014 end-page: 3833 article-title: Enzyme‐ and transporter‐mediated drug interactions with small molecule tyrosine kinase inhibitors publication-title: J Pharm Sci – volume: 36 start-page: 603 issue: 9 year: 2015 end-page: 612 article-title: Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone publication-title: Biopharm Drug Dispos – volume: 71 start-page: 617 issue: 5 year: 2015 end-page: 624 article-title: Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway publication-title: Eur J Clin Pharmacol – volume: 101 start-page: 2186 issue: 10 year: 2010 end-page: 2192 article-title: Trough plasma concentration of imatinib reflects BCR‐ABL kinase inhibitory activity and clinical response in chronic‐phase chronic myeloid leukemia: a report from the BINGO study publication-title: Cancer Sci – volume: 10 start-page: 854 year: 2019 article-title: Genetic polymorphisms and adverse events on unbound imatinib and its active metabolite concentration in patients with gastrointestinal stromal tumors publication-title: Front Pharmacol – volume: 56 start-page: 977 issue: 8 year: 2017 end-page: 985 article-title: genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients publication-title: Clin Pharmacokinet – volume: 302 start-page: 475 issue: 2 year: 2002 end-page: 482 article-title: Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes publication-title: J Pharmacol Exp Ther – volume: 127 start-page: 221 issue: 4 year: 2012 end-page: 227 article-title: Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients publication-title: Acta Haematol – year: 2015 – volume: 50 start-page: 452 issue: 7–8 year: 2017 end-page: 454 article-title: The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study publication-title: Clin Biochem – volume: 5 start-page: 77 issue: 1 year: 2016 end-page: 79 article-title: P < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 publication-title: J Sport Health Sci – volume: 13 start-page: 7394 issue: 24 year: 2007 end-page: 7400 article-title: Influence of CYP3A4 inhibition on the steady‐state pharmacokinetics of imatinib publication-title: Clin Cancer Res – volume: 5 start-page: 367 issue: 7 year: 2016 end-page: 376 article-title: Towards a best practice approach in PBPK modeling: case example of developing a unified efavirenz model accounting for induction of CYPs 3A4 and 2B6 publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 58 start-page: 911 issue: 7 year: 2019 end-page: 926 article-title: Physiologically based pharmacokinetic modelling of hyperforin to predict drug interactions with St John's wort publication-title: Clin Pharmacokinet – volume: 14 start-page: 7102 issue: 21 year: 2008 end-page: 7109 article-title: Population pharmacokinetics and pharmacogenetics of imatinib in children and adults publication-title: Clin Cancer Res – volume: 111 start-page: 4022 issue: 8 year: 2008 end-page: 4028 article-title: Imatinib pharmacokinetics and its correlation with response and safety in chronic‐phase chronic myeloid leukemia: a subanalysis of the IRIS study publication-title: Blood – volume: 4 start-page: 605 issue: 10 year: 2015 end-page: 613 article-title: Development of a multicompartment permeability‐limited lung PBPK model and its application in predicting pulmonary pharmacokinetics of antituberculosis drugs publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 37 start-page: 276 issue: 2 year: 2016 end-page: 284 article-title: Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration publication-title: Acta Pharmacol Sin – volume: 18 start-page: 603 issue: 3 year: 2017 article-title: Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients publication-title: Int J Mol Sci – volume: 92 start-page: 17 issue: 1 year: 2012 end-page: 20 article-title: Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions publication-title: Clin Pharmacol Ther – volume: 57 start-page: 31 issue: 4 year: 2016 end-page: 38 article-title: Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real‐life setting publication-title: Eur J Cancer – volume: 33 start-page: 1503 issue: 10 year: 2005 end-page: 1512 article-title: Metabolism and disposition of imatinib mesylate in healthy volunteers publication-title: Drug Metab Dispos – volume: 28 issue: 15_suppl year: 2010 article-title: Pharmacokinetic differences and ethnic variability in tolerance of cytotoxic drugs publication-title: J Clin Oncol – volume: 103 start-page: 553 issue: 7 year: 2011 end-page: 561 article-title: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib publication-title: J Natl Cancer Inst – volume: 85 start-page: 100 issue: 1 year: 2019 end-page: 113 article-title: Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children publication-title: Br J Clin Pharmacol – ident: e_1_2_11_75_1 doi: 10.1111/j.1365-2125.2006.02719.x – ident: e_1_2_11_88_1 doi: 10.1016/j.leukres.2010.09.014 – ident: e_1_2_11_22_1 doi: 10.1002/cpt.1076 – ident: e_1_2_11_26_1 doi: 10.1002/cpt.1240 – ident: e_1_2_11_105_1 doi: 10.1159/000484102 – ident: e_1_2_11_63_1 doi: 10.1111/bph.14753 – ident: e_1_2_11_80_1 doi: 10.1016/j.clinthera.2019.10.009 – ident: e_1_2_11_82_1 doi: 10.1200/JCO.2009.25.3724 – ident: e_1_2_11_12_1 doi: 10.1182/blood-2007-10-116475 – ident: e_1_2_11_86_1 doi: 10.1007/s40261-020-00921-7 – ident: e_1_2_11_70_1 doi: 10.1158/1078-0432.CCR-07-0346 – ident: e_1_2_11_98_1 doi: 10.1016/j.clinbiochem.2016.12.006 – ident: e_1_2_11_92_1 doi: 10.2217/pgs-2018-0139 – volume: 139 start-page: 1 issue: 105061 year: 2019 ident: e_1_2_11_27_1 article-title: Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically‐based pharmacokinetic modelling publication-title: Eur J Pharm Sci – ident: e_1_2_11_20_1 doi: 10.1038/clpt.1990.111 – ident: e_1_2_11_13_1 doi: 10.1002/cpt.787 – ident: e_1_2_11_94_1 doi: 10.1182/blood-2006-07-036012 – ident: e_1_2_11_38_1 doi: 10.1124/jpet.116.233635 – ident: e_1_2_11_67_1 doi: 10.1002/psp4.12615 – ident: e_1_2_11_73_1 doi: 10.1002/jcph.953 – ident: e_1_2_11_68_1 doi: 10.1002/bdd.2257 – ident: e_1_2_11_41_1 doi: 10.1002/bdd.1987 – ident: e_1_2_11_85_1 doi: 10.1007/s00280-003-0756-z – ident: e_1_2_11_36_1 – ident: e_1_2_11_16_1 doi: 10.1007/s40262-013-0089-y – ident: e_1_2_11_84_1 doi: 10.1016/j.tips.2016.08.003 – ident: e_1_2_11_107_1 doi: 10.3390/ijms18030603 – ident: e_1_2_11_5_1 doi: 10.1111/bcp.13327 – ident: e_1_2_11_56_1 doi: 10.2217/pgs.09.82 – ident: e_1_2_11_50_1 doi: 10.1124/jpet.102.033837 – ident: e_1_2_11_57_1 doi: 10.1038/leu.2008.245 – ident: e_1_2_11_4_1 doi: 10.1097/FTD.0b013e318284ef11 – ident: e_1_2_11_74_1 doi: 10.1158/1078-0432.CCR-05-2596 – ident: e_1_2_11_32_1 doi: 10.1038/clpt.2012.68 – ident: e_1_2_11_79_1 doi: 10.1016/j.clpt.2006.05.003 – ident: e_1_2_11_52_1 – ident: e_1_2_11_51_1 doi: 10.1124/dmd.114.058099 – ident: e_1_2_11_10_1 doi: 10.1002/jps.24113 – ident: e_1_2_11_93_1 doi: 10.18433/jpps30559 – ident: e_1_2_11_46_1 doi: 10.1592/phco.24.16.1508.50958 – ident: e_1_2_11_103_1 doi: 10.1007/s12185-011-0838-3 – ident: e_1_2_11_60_1 doi: 10.1038/clpt.2010.186 – ident: e_1_2_11_55_1 doi: 10.1124/dmd.109.031542 – ident: e_1_2_11_78_1 doi: 10.1111/bcp.13990 – ident: e_1_2_11_17_1 doi: 10.1200/jco.2010.28.15_suppl.e13034 – ident: e_1_2_11_108_1 doi: 10.3389/fphar.2019.00854 – ident: e_1_2_11_9_1 doi: 10.1111/j.1476-5381.2010.00946.x – ident: e_1_2_11_83_1 doi: 10.1038/sj.clpt.6100201 – ident: e_1_2_11_40_1 doi: 10.18433/J3159D – ident: e_1_2_11_58_1 doi: 10.1007/s00277-013-1937-4 – ident: e_1_2_11_29_1 doi: 10.1111/jcpt.12424 – ident: e_1_2_11_101_1 doi: 10.1007/s12185-009-0263-z – ident: e_1_2_11_95_1 doi: 10.1016/j.leukres.2008.07.015 – ident: e_1_2_11_48_1 doi: 10.2174/138920008784746382 – ident: e_1_2_11_37_1 doi: 10.1002/psp4.12034 – ident: e_1_2_11_64_1 doi: 10.1080/10826076.2015.1025143 – ident: e_1_2_11_61_1 doi: 10.1016/j.jshs.2016.01.019 – ident: e_1_2_11_19_1 doi: 10.1111/j.1365-2125.2004.02117.x – ident: e_1_2_11_34_1 doi: 10.1080/00498250600683262 – ident: e_1_2_11_59_1 doi: 10.3322/caac.21551 – ident: e_1_2_11_15_1 doi: 10.1093/annonc/mdx219 – ident: e_1_2_11_28_1 doi: 10.1093/jnci/djr060 – ident: e_1_2_11_35_1 doi: 10.1016/j.ijid.2016.10.008 – ident: e_1_2_11_47_1 doi: 10.1038/clpt.2013.92 – ident: e_1_2_11_6_1 doi: 10.1124/dmd.105.004283 – ident: e_1_2_11_100_1 doi: 10.1007/s12185-009-0315-4 – volume: 1 start-page: 1 issue: 9 year: 2013 ident: e_1_2_11_30_1 article-title: The Simcyp population based simulator: architecture, implementation, and quality assurance publication-title: In Silico Pharmacol – ident: e_1_2_11_23_1 doi: 10.1007/s00228-015-1834-y – ident: e_1_2_11_65_1 doi: 10.1007/s40262-016-0494-0 – ident: e_1_2_11_106_1 doi: 10.1159/000336244 – volume: 33 start-page: 244 issue: 2 year: 2011 ident: e_1_2_11_89_1 article-title: Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia publication-title: Ther Drug Monit – ident: e_1_2_11_39_1 doi: 10.1111/j.1365-2125.2011.04076.x – volume: 9 start-page: 625 issue: 2 year: 2003 ident: e_1_2_11_43_1 article-title: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients publication-title: Clin Cancer Res – ident: e_1_2_11_7_1 doi: 10.1124/dmd.112.048017 – ident: e_1_2_11_97_1 doi: 10.1007/s40262-016-0441-0 – volume: 39 start-page: 298 issue: 5 year: 2010 ident: e_1_2_11_31_1 article-title: Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time‐dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—the effect of diltiazem on the time‐course of exposure to triazolam publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2009.12.002 – ident: e_1_2_11_81_1 doi: 10.1038/aps.2010.79 – ident: e_1_2_11_45_1 doi: 10.1111/bcp.12702 – ident: e_1_2_11_71_1 doi: 10.2174/157488408785747656 – ident: e_1_2_11_76_1 doi: 10.1111/j.1365-2125.2012.04422.x – ident: e_1_2_11_42_1 doi: 10.3389/fphar.2019.01672 – ident: e_1_2_11_72_1 doi: 10.1111/ped.12382 – ident: e_1_2_11_54_1 doi: 10.1016/j.ejps.2020.105355 – ident: e_1_2_11_53_1 doi: 10.1007/s00228-012-1467-3 – volume: 36 start-page: 1 issue: 2 year: 2018 ident: e_1_2_11_77_1 article-title: Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha‐1‐acid glycoprotein publication-title: Pharm Res – ident: e_1_2_11_2_1 doi: 10.1056/NEJMoa1609324 – ident: e_1_2_11_99_1 doi: 10.1007/s00228-020-02888-y – ident: e_1_2_11_11_1 doi: 10.1200/JCO.2009.26.3087 – ident: e_1_2_11_102_1 doi: 10.1111/j.1349-7006.2010.01643.x – ident: e_1_2_11_66_1 doi: 10.1111/bcp.13764 – ident: e_1_2_11_69_1 doi: 10.1007/s40262-019-00736-6 – ident: e_1_2_11_25_1 doi: 10.1038/aps.2015.122 – ident: e_1_2_11_62_1 doi: 10.1111/bph.14752 – ident: e_1_2_11_24_1 doi: 10.1007/s40262-015-0356-1 – ident: e_1_2_11_18_1 doi: 10.1111/j.1476-5381.2011.01732.x – ident: e_1_2_11_91_1 doi: 10.1111/j.1365-2125.2008.03150.x – ident: e_1_2_11_14_1 doi: 10.3324/haematol.2011.045666 – ident: e_1_2_11_96_1 doi: 10.1016/j.ejca.2015.12.029 – ident: e_1_2_11_44_1 doi: 10.1158/1078-0432.CCR-08-0950 – ident: e_1_2_11_33_1 doi: 10.1002/psp4.12088 – ident: e_1_2_11_87_1 doi: 10.1007/s10147-007-0746-y – ident: e_1_2_11_90_1 doi: 10.1093/chromsci/bmt037 – ident: e_1_2_11_3_1 doi: 10.1007/s40262-016-0439-7 – ident: e_1_2_11_104_1 doi: 10.1111/j.1349-7006.2012.02253.x – ident: e_1_2_11_49_1 doi: 10.1007/s00280-003-0722-9 – ident: e_1_2_11_21_1 doi: 10.1002/psp4.12392 – ident: e_1_2_11_8_1 doi: 10.21037/tcr.2017.09.08 |
| SSID | ssj0013165 |
| Score | 2.4522421 |
| Snippet | Aims
This study implements a physiologically‐based pharmacokinetic (PBPK) modelling approach to investigate inter‐ethnic differences in imatinib... This study implements a physiologically-based pharmacokinetic (PBPK) modelling approach to investigate inter-ethnic differences in imatinib pharmacokinetics... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1735 |
| SubjectTerms | ethnic differences imatinib physiologically‐based pharmacokinetic simulation |
| Title | Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.15084 https://www.ncbi.nlm.nih.gov/pubmed/34535920 https://www.proquest.com/docview/2574406248 |
| Volume | 88 |
| WOSCitedRecordID | wos000707392800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2125 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VwoFLecNCWRmEKg4N2jh2EqsnKKxAqlYr1Iq9RY4fYkXJrjbbSnvjyJHf2F_SGSfZpTwkJG6WMraseDz-xuP5BuCFSiX3iqdRKQYuEnqgohybkeOZtTrh2rtA4nqUjUb5ZKLGW3DQ5cI0_BDrCzfaGcFe0wbXZf3TJi_N_BWRmRMXaCxiql7w6cNoE0GIQxlJgsTobMm4ZRWiVzzrnlfPot8A5lW8Gg6c4a3_mupt2GlxJnvdKMYd2HLVXdgbN0TVq312vMm7qvfZHhtvKKxX9-B7eBja2cXT1cW3H3TcWTZvxb7gnLArC4V02HxB4Z6gwWzmGVFQLLCLW36uUKarwYIWCT-xKWHkalr-OlbNdGWZndHlBaN6EV_Rw74PJ8N3x4fvo7ZmQ2SSlIIssRK-dNzKUnqfC4U2QetUmtglRmbW8zxOlfKIMqXTypjcpegTelwnI4V1yQPYrmaVewTMIjYqyX0zyUAIXqo4sRklfksjiAewBy-71StMS2hOdTVOi86xwf9ehP_eg-dr0XnD4vEnoWedChS4xyhwois3O6sLNGsCgQ8XeQ8eNrqxHiYRMpGKD3A2QQX-Pn7x5nAcGo__XfQJ3OSUbxGeie_C9nJx5p7CDXO-nNaLPlzLJnkfrr_9ODw56gf9vwQEawnF |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxEB5RWqlc6BMIbalbVYgDi7Jee7OWemkRCNQ0yiEIbqtdP0QEbKIkIOXGkSO_kV_CjHc3KbSVKvVmaceWtR6Pv_F4vgH4omLJneJxkIumDUTWVEGCzcDyljFZxDNnPYlru9XpJCcnqrsAX-tcmJIfYnbhRjvD22va4HQh_csuz_Vwh9jMxRN4KhBoUOGG48POPIYQ-kKSBIrR3ZJhxStE73hmXR-eRr9BzIeI1R85-y_-b7IvYbmCmuxbqRuvYMEWr2GzW3JVT7dZb556Nd5mm6w7Z7GevoEb_za0No3n07vrWzrxDBtWYmc4KezKfC0dNhxRxMcrMRs4RiwUI-xiJ6cFytRlWNAo4SfWJ5hc9PPHY41ZVhhmBnR_wahkxAU62W_haH-vt3sQVGUbAh3FFGcJlXC55Ubm0rlEKDQLWRZLHdpIy5ZxPAljpRwCTWkzpXViY3QLHS6UlsLYaAUWi0Fh14AZhEc5eXA6agrBcxVGpkW531ILogJswFa9fKmuOM2ptMZ5Wvs2-N9T_98b8HkmOiyJPP4k9KnWgRS3GcVOssIOLscpWjaB2IeLpAGrpXLMhomEjKTiTZyN14G_j59-3-36xvq_i36E5we9n-20fdj58Q6WOKVf-Ffj72FxMrq0H-CZvpr0x6MNr_737S0LWw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VLUJcoDxatrRgEKo4NGjj2NlY4tIHKxCrVYRaqbco8UOsWrLR7hZpbxx75DfyS5hxkt2Wh4TEzVLGlhWPx994PN8AvFKx5E7xOChEzwYi76kgwWZged-YPOK5s57EddgfjZKzM5Wuwds2F6bmh1heuNHO8PaaNritjLu2ywtdvSE2c3EL1gUVkenA-vGnwelwFUUIfSlJgsXocMmwYRailzzLzjfPo99A5k3M6g-dwf3_m-4G3GvAJjuoteMBrNnyIeylNVv1Yp-drJKvZvtsj6UrHuvFI7jyr0Nb43ix-PHtO515hlWN2DlOCrsyX02HVVOK-Xg1ZhPHiIdiil3s_HOJMm0hFjRL-ImNCSiX4-LXsWYsLw0zE7rBYFQ04gu62Y_hdPDu5Oh90BRuCHQUU6QlVMIVlhtZSOcSodAw5HksdWgjLfvG8SSMlXIINaXNldaJjdExdLhQWgpjo03olJPSPgFmECAV5MPpqCcEL1QYmT5lf0stiAywC6_b5ct0w2pOxTUusta7wf-e-f_ehZdL0aqm8viT0ItWBzLcaBQ9yUs7uZxlaNsEoh8uki5s1cqxHCYSMpKK93A2Xgf-Pn52eJT6xva_iz6HO-nxIBt-GH18Cnc55V_4Z-M70JlPL-0u3NZf5-PZ9Fmj_z8BnX0MBA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Physiologically%E2%80%90based+pharmacokinetic+model+predictions+of+inter%E2%80%90ethnic+differences+in+imatinib+pharmacokinetics+and+dosing+regimens&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Adiwidjaja%2C+Jeffry&rft.au=Gross%2C+Annette+S.&rft.au=Boddy%2C+Alan+V.&rft.au=McLachlan%2C+Andrew+J.&rft.date=2022-02-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=88&rft.issue=4&rft.spage=1735&rft.epage=1750&rft_id=info:doi/10.1111%2Fbcp.15084&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bcp_15084 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |